Emma Copland

Jul 8, 2024 | nature.com | Emma Copland |Defne Saatci |Nicholas L. Mills |Paul Moss |Aziz Sheikh |Chris Robertson

Correction to: Nature Communications https://doi.org/10.1038/s41467-024-47745-z, published online 27 May 2024The original version of this article contained information on vaccine dose amount (full or half) in Table 2 and Supplementary Table 1. This has subsequently been found to be inaccurate due to inconsistent coding in the raw data. The vaccine dose amount has therefore been removed from Table 2 and Supplementary Table 1. This data was not used elsewhere in the analysis.

May 27, 2024 | nature.com | Emma Copland |Defne Saatci |Nicholas L. Mills |Paul Moss |Aziz Sheikh |Chris Robertson

AbstractThe risk-benefit profile of COVID-19 vaccination in children remains uncertain. A self-controlled case-series study was conducted using linked data of 5.1 million children in England to compare risks of hospitalisation from vaccine safety outcomes after COVID-19 vaccination and infection. In 5-11-year-olds, we found no increased risks of adverse events 1–42 days following vaccination with BNT162b2, mRNA-1273 or ChAdOX1.